Concentration and integrity indexes of urine cell-free DNA as promising biomarkers for early lung cancer diagnosis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018). • Introduces the status report on the global burden of cancer in 2018, of which, lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death.
  MedlineGoogle Scholar
• 2. Ost D, Fein AM, Feinsilver SH. Clinical practice. the solitary pulmonary nodule. N. Engl. J. Med. 348(25), 2535–2542 (2003).
  MedlineGoogle Scholar
• 3. Gohagan JK, Marcus PM, Fagerstrom RM et al. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer 47(1), 9–15 (2005).
  MedlineGoogle Scholar
• 4. Church TR, Black WC, Aberle DR et al. Results of initial low-dose computed tomographic screening for lung cancer. N. Engl. J. Med. 368(21), 1980–1991 (2013).
  MedlineGoogle Scholar
• 5. Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 76(2), 138–143 (2012).
  Medline CASGoogle Scholar
• 6. Kucera R, Topolcan O, Fiala O et al. The role of TPS and TPA in the diagnostics of distant metastases. Anticancer Res. 36(2), 773–777 (2016).
  Medline CASGoogle Scholar
• 7. Van Berckelaer C, Brouwers AJ, Peeters DJ et al. Current and future role of circulating tumor cells in patients with epithelial ovarian cancer. Eur. J. Surg. Oncol. 42(12), 1772–1779 (2016).
  Medline CASGoogle Scholar
• 8. Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23(7), 1420–1430 (2005). • Describes circulating tumor cells could be used as a novel prognostic biomarker for diagnosed metastatic breast cancer.
  MedlineGoogle Scholar
• 9. Madhavan D, Zucknick M, Wallwiener M et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin. Cancer Res. 18(21), 5972–5982 (2012).
  Medline CASGoogle Scholar
• 10. Hao TB, Shi W, Shen XJ et al. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br. J. Cancer 111(8), 1482–1489 (2014). • Describes circulating cell-free DNA (cfDNA) in serum as a promising biomarker for diagnosis and prognostic prediction of colorectal cancer.
  Medline CASGoogle Scholar
• 11. Kalluri R. The biology and function of exosomes in cancer. J. Clin. Invest. 126(4), 1208–1215 (2016).
  MedlineGoogle Scholar
• 12. Giacona MB, Ruben GC, Iczkowski KA et al. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 17(1), 89–97 (1998).
  Medline CASGoogle Scholar
• 13. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284(5756), 555–556 (1980).
  Medline CASGoogle Scholar
• 14. Umetani N, Giuliano AE, Hiramatsu SH et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J. Clin. Oncol. 24(26), 4270–4276 (2006). • Describes serum cfDNA integrity as a biomarker for prediction of breast tumor progression.
  Medline CASGoogle Scholar
• 15. Tissot C, Toffart AC, Villar S et al. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur. Respir. J. 46(6), 1773–1780 (2015).
  Medline CASGoogle Scholar
• 16. Umetani N, Kim J, Hiramatsu S et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin. Chem. 52(6), 1062–1069 (2006). •• Evaluates serum cfDNA integrity as a potential biomarker for differentiating colorectal cancer or periampullary cancer from healthy individuals.
  Medline CASGoogle Scholar
• 17. Pu WY, Zhang R, Xiao L et al. Prediction of cancer progression in a group of 73 gastric cancer patients by circulating cell-free DNA. BMC Cancer 16(1), 943 (2016).
  MedlineGoogle Scholar
• 18. Ellinger J, Wittkamp V, Albers P et al. Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J. Urol. 181(1), 363–371 (2009). •• Evaluates the diagnostic value of cfDNA integrity in patients with testicular germ cell cancer.
  Medline CASGoogle Scholar
• 19. Catarino R, Ferreira MM, Rodrigues H et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol. 27(8), 415–421 (2008).
  Medline CASGoogle Scholar
• 20. Reckamp KL, Melnikova VO, Karlovich C et al. A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J. Thorac. Oncol. 11(10), 1690–1700 (2016).
  MedlineGoogle Scholar
• 21. Szarvas T, Kovalszky I, Bedi K et al. Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment. Oncol. Rep. 18(2), 405–409 (2007).
  Medline CASGoogle Scholar
• 22. Su YH, Song J, Wang Z et al. Removal of high-molecular-weight DNA by carboxylated magnetic beads enhances the detection of mutated K-ras DNA in urine. Ann. NY Acad. Sci. 1137(1), 82–91 (2008). •• Describes mutated K-ras gene can be detected in urine DNA.
  Medline CASGoogle Scholar
• 23. Ghanjati F, Beermann A, Hermanns T et al. Unreserved application of epigenetic methods to define differences of DNA methylation between urinary cellular and cell-free DNA. Cancer Biomark. 14(5), 295–302 (2014).
  Medline CASGoogle Scholar
• 24. Woodson K, O'Reilly KJ, Hanson JC et al. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J. Urol. 179(2), 508–511 (2008).
  Medline CASGoogle Scholar
• 25. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 409(6822), 860–921 (2001).
  Medline CASGoogle Scholar
• 26. Hwu HR, Roberts JW, Davidson EH et al. Insertion and/or deletion of many repeated DNA sequences in human and higher ape evolution. Proc. Natl Acad. Sci. 83(11), 3875–3879 (1986).
  Medline CASGoogle Scholar
• 27. Botezatu I, Serdyuk O, Potapova G et al. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin. Chem. 46(1), 1078–1084 (2000). •• Describes a new approach for detecting specific genomic DNA sequences in urine.
  Medline CASGoogle Scholar
• 28. Lichtenstein AV, Melkonyan HS, Tomei LD et al. Circulating nucleic acids and apoptosis. Ann. NY Acad. Sci. 945(1), 239–249 (2001).
  Medline CASGoogle Scholar
• 29. Yao W, Mei C, Nan X, Hui L. Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: a qualitative study. Gene 590(1), 142–148 (2016).
  Medline CASGoogle Scholar